Azitra (AZTR) Common Equity (2022 - 2026)
Azitra's (AZTR) quarterly Common Equity came in at $10.5 million in Q1 2026, up 137.7% YoY from $4.4 million in Q1 2025, and up 175.71% on a QoQ basis from $3.8 million in Q4 2025.
Azitra (AZTR) Common Equity (2022 - 2026) Analysis & Trends
Azitra (AZTR) has 5 years of Common Equity data on file, last reported at $10.5 million in Q1 2026.
- Quarterly Common Equity rose 137.7% year-over-year to $10.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.5 million (up 137.7% YoY) and the FY2025 annual result came in at $3.8 million, down 33.29% from the prior year.
- Common Equity grew to $10.5 million in Q1 2026, from $3.8 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $10.5 million in Q1 2026 to a low of -$38.7 million in Q1 2023.
- A 5-year average of -$4.9 million and a median of $3.4 million in 2023 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2024 — Common Equity plunged 76.15% — and 2026, when it soared 137.7%.
- Tracing AZTR's Common Equity over 5 years: stood at -$36.3 million in 2022, then surged by 108.03% to $2.9 million in 2023, then jumped by 95.61% to $5.7 million in 2024, then plunged by 33.29% to $3.8 million in 2025, then jumped by 175.71% to $10.5 million in 2026.
- The last three Common Equity figures came in at $10.5 million (Q1 2026), $3.8 million (Q4 2025), and $2.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | Azitra | 2.44 Mn | 2.44 Mn | - | 7.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.33 Mn |
| Mar 31, 2026 | 10.48 Mn |
| Dec 31, 2025 | 3.80 Mn |
| Sep 30, 2025 | 2.28 Mn |
| Jun 30, 2025 | 2.20 Mn |
| Mar 31, 2025 | 4.41 Mn |
| Dec 31, 2024 | 5.70 Mn |
| Sep 30, 2024 | 8.06 Mn |
| Jun 30, 2024 | 1.73 Mn |
| Mar 31, 2024 | 4.32 Mn |
| Dec 31, 2023 | 2.91 Mn |
| Sep 30, 2023 | 5.33 Mn |
| Jun 30, 2023 | 7.24 Mn |
| Mar 31, 2023 | -38.68 Mn |
| Dec 31, 2022 | -36.26 Mn |
| Sep 30, 2022 | -32.24 Mn |
| Jun 30, 2022 | -29.87 Mn |